NCT07104643View on ClinicalTrials.gov

Study of TYK-00540 Combined With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC）

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions

mCRPC

Interventions

DRUG

TYK-00540

Take the specified dose (20mg or 30mg) orally twice a day. Take it on an empty stomach in the morning with about 200 mL of warm water.

DRUG

Enzalutamide

Take orally, 160mg each time, once a day. Take orally with or without meals.

Trial Locations (1)

Unknown

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors

lead

TYK Medicines, Inc

INDUSTRY

NCT07104643 - Study of TYK-00540 Combined With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC） | Biotech Hunter | Biotech Hunter